Xilio Development Inc (XLO) - Net Assets
Based on the latest financial reports, Xilio Development Inc (XLO) has net assets worth $72.26 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($154.25 Million) and total liabilities ($81.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Xilio Development Inc to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $72.26 Million |
| % of Total Assets | 46.85% |
| Annual Growth Rate | -1.45% |
| 5-Year Change | -80.98% |
| 10-Year Change | N/A |
| Growth Volatility | 71.85 |
Xilio Development Inc - Net Assets Trend (2019–2025)
This chart illustrates how Xilio Development Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Xilio Development Inc.
Annual Net Assets for Xilio Development Inc (2019–2025)
The table below shows the annual net assets of Xilio Development Inc from 2019 to 2025. Also explore Xilio Development Inc net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $35.27 Million | +100.44% |
| 2024-12-31 | $17.60 Million | -52.21% |
| 2023-12-31 | $36.83 Million | -65.14% |
| 2022-12-31 | $105.65 Million | -43.03% |
| 2021-12-31 | $185.43 Million | +3608.59% |
| 2020-12-31 | $-5.29 Million | -113.72% |
| 2019-12-31 | $38.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xilio Development Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38892200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $36.89 Million | 104.59% |
| Other Components | $417.17 Million | 1182.69% |
| Total Equity | $35.27 Million | 100.00% |
Xilio Development Inc Competitors by Market Cap
The table below lists competitors of Xilio Development Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SensorView Co Ltd
KQ:321370
|
$59.03 Million |
|
AML3D Ltd
AU:AL3
|
$59.07 Million |
|
Hindustan Composites Limited
NSE:HINDCOMPOS
|
$59.08 Million |
|
Nahar Poly Films Limited
NSE:NAHARPOLY
|
$59.11 Million |
|
OnMobile Global Limited
NSE:ONMOBILE
|
$59.00 Million |
|
Top Systems-L
TA:TOPS
|
$58.96 Million |
|
Dutaland Bhd
KLSE:3948
|
$58.92 Million |
|
JLS Co.Ltd
KQ:040420
|
$58.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xilio Development Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 17,598,000 to 35,273,000, a change of 17,675,000 (100.4%).
- Net loss of 35,036,000 reduced equity.
- Share repurchases of 2,810,000 reduced equity.
- New share issuances of 40,655,000 increased equity.
- Other factors increased equity by 14,866,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-35.04 Million | -99.33% |
| Share Repurchases | $2.81 Million | -7.97% |
| Share Issuances | $40.66 Million | +115.26% |
| Other Changes | $14.87 Million | +42.15% |
| Total Change | $- | 100.44% |
Book Value vs Market Value Analysis
This analysis compares Xilio Development Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 21.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.01x to 21.42x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1317.21 | $9.04 | x |
| 2020-12-31 | $-141.26 | $9.04 | x |
| 2021-12-31 | $463.05 | $9.04 | x |
| 2022-12-31 | $3.86 | $9.04 | x |
| 2023-12-31 | $18.75 | $9.04 | x |
| 2024-12-31 | $4.60 | $9.04 | x |
| 2025-12-31 | $0.42 | $9.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xilio Development Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -99.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -80.05%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 4.39x
- Recent ROE (-99.33%) is above the historical average (-115.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -44.95% | 0.00% | 0.00x | 1.63x | $-21.16 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-54.69 Million |
| 2021 | -40.07% | 0.00% | 0.00x | 1.20x | $-92.84 Million |
| 2022 | -82.63% | 0.00% | 0.00x | 1.32x | $-97.86 Million |
| 2023 | -207.47% | 0.00% | 0.00x | 1.65x | $-80.09 Million |
| 2024 | -330.95% | -918.05% | 0.09x | 4.04x | $-60.00 Million |
| 2025 | -99.33% | -80.05% | 0.28x | 4.39x | $-38.56 Million |
Industry Comparison
This section compares Xilio Development Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xilio Development Inc (XLO) | $72.26 Million | -44.95% | 1.13x | $59.02 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Xilio Development Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumo… Read more